Jazz Pharmaceuticals plc Quarterly Amortization of Intangible Assets in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
Summary
Jazz Pharmaceuticals plc quarterly/annual Amortization of Intangible Assets history and growth rate from Q2 2010 to Q3 2024.
  • Jazz Pharmaceuticals plc Amortization of Intangible Assets for the quarter ending September 30, 2024 was $157M, a 1.66% increase year-over-year.
  • Jazz Pharmaceuticals plc Amortization of Intangible Assets for the twelve months ending September 30, 2024 was $620M, a 4.35% increase year-over-year.
  • Jazz Pharmaceuticals plc annual Amortization of Intangible Assets for 2023 was $608M, a 1.52% increase from 2022.
  • Jazz Pharmaceuticals plc annual Amortization of Intangible Assets for 2022 was $599M, a 14% increase from 2021.
  • Jazz Pharmaceuticals plc annual Amortization of Intangible Assets for 2021 was $526M, a 103% increase from 2020.
Amortization of Intangible Assets, Trailing 12 Months (USD)
Amortization of Intangible Assets, Quarterly (USD)
Amortization of Intangible Assets, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $620M $157M +$2.57M +1.66% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $617M $155M +$3.16M +2.08% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $614M $156M +$5.94M +3.97% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $608M $152M +$14.2M +10.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $594M $155M +$13.7M +9.67% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $580M $152M +$3.61M +2.43% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $577M $150M -$22.3M -13% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $599M $137M -$19.9M -12.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $619M $141M -$18.6M -11.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $638M $148M +$7.98M +5.68% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $630M $172M +$104M +152% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $526M $157M +$90.2M +135% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $436M $160M +$93.1M +140% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $342M $140M +$77.5M +123% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $265M $68.2M +$5.35M +8.51% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $260M $67.1M -$106M -61.3% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-01
Q3 2020 $366M $66.7M +$3.82M +6.08% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $362M $63M +$1.4M +2.27% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $361M $62.8M +$5.96M +10.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $355M $173M +$127M +273% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $228M $62.9M +$15.9M +33.8% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-02
Q2 2019 $212M $61.6M +$6.62M +12% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $205M $56.9M +$3.88M +7.32% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q4 2018 $201M $46.5M -$6.36M -12% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-23
Q3 2018 $208M $47M -$324K -0.69% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $208M $55M +$28.8M +110% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $179M $53M +$27.3M +107% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 $152M $52.9M +$26.7M +102% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-25
Q3 2017 $125M $47.3M +$20.9M +78.9% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 $104M $26.2M -$551K -2.06% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $105M $25.7M +$3.02M +13.4% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 $102M $26.2M +$2.47M +10.4% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-26
Q3 2016 $99.5M $26.5M +$326K +1.25% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 $99.2M $26.7M +$3.07M +13% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-08
Q1 2016 $96.1M $22.6M -$2.04M -8.25% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
Q4 2015 $98.2M $23.7M -$8.29M -25.9% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-27
Q3 2015 $106M $26.1M -$4.5M -14.7% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-08
Q2 2015 $111M $23.7M -$9.13M -27.8% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 $120M $24.7M -$6.51M -20.9% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q4 2014 $127M $32M Oct 1, 2014 Dec 31, 2014 10-K 2017-02-28
Q3 2014 $30.6M Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-09
Q2 2014 $32.8M Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-05
Q1 2014 $31.2M +$11.6M +59.5% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-07
Q1 2013 $19.6M +$6.04M +44.7% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-08
Q2 2012 $33M $15.8M +$13.9M +746% Apr 1, 2012 Jun 30, 2012 10-Q 2012-08-07
Q1 2012 $19.1M $13.5M +$11.7M +626% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-07
Q4 2011 $7.45M $1.86M Oct 1, 2011 Dec 31, 2011 10-K 2014-02-25
Q3 2011 $1.86M $0 0% Jul 1, 2011 Sep 30, 2011 10-Q 2011-11-08
Q2 2011 $1.86M -$182K -8.9% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-07
Q1 2011 $1.86M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-08
Q3 2010 $1.86M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-08
Q2 2010 $2.04M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.